1. Home
  2. NEXA vs DFTX Comparison

NEXA vs DFTX Comparison

Compare NEXA & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexa Resources S.A.

NEXA

Nexa Resources S.A.

HOLD

Current Price

$14.42

Market Cap

1.9B

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$22.29

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NEXA
DFTX
Founded
1956
N/A
Country
Luxembourg
United States
Employees
5612
N/A
Industry
Metal Mining
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
NEXA
DFTX
Price
$14.42
$22.29
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
$10.40
$38.50
AVG Volume (30 Days)
1.4M
2.0M
Earning Date
05-06-2026
05-04-2026
Dividend Yield
0.89%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.69
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.62
$14.62
52 Week High
$16.75
$26.25

Technical Indicators

Market Signals
Indicator
NEXA
DFTX
Relative Strength Index (RSI) 62.86 60.63
Support Level $10.72 $16.37
Resistance Level $14.84 N/A
Average True Range (ATR) 1.06 1.39
MACD 0.25 0.04
Stochastic Oscillator 62.50 40.92

Price Performance

Historical Comparison
NEXA
DFTX

About NEXA Nexa Resources S.A.

Nexa Resources SA operate large-scale, mechanized underground and open pit mines, as well as smelters. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: